The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Subscribe To Our Newsletter & Stay Updated
